The China NMPA's CDE has granted approval to the IND application of InnoCare Pharma to initiate the trial of ICP-B794.

BioAtla has presented first-in-human Phase I study data of its anticancer therapy, BA3182, targeting those with metastatic adenocarcinoma.

Novartis’ Cosentyx (secukinumab) has failed to show any benefit in the Phase III study in adults with newly diagnosed or relapsing giant cell arteritis (GCA). In the GCAptAIN trial (NCT04930094), ...

Belite Bio has completed enrolment in the 24-month PHOENIX Phase III trial assessing the tolerability and safety of oral Tinlarebant.

The UK Government is pushing for a single, unified digital patient record within the NHS, but experts have shared cybersecurity concerns.

Ascletis Pharma has dosed the first obese or overweight subjects in the 13-week, multi-centre US Phase IIa trial of ASC30.

Opioid use disorder (OUD) has become a mounting public health crisis in the US, often disproportionately affecting individuals in the most vulnerable socioeconomic statuses.

Experts at HLTH Europe discussed how to ensure patients have trust in the EHDS to ensure a successful roll-out.

Organon is terminating development of its endometriosis drug after the Phase II trial failed to show any benefit. The ELENA proof-of-concept study (NCT05560646) was evaluating Organon’s therapy, ...

Bio-Thera Solutions has announced the early termination of its pivotal Phase II/III clinical trial of BAT4406F for NMOSD.

The companies are also running an open-label study to evaluate the long-term efficacy and safety of the psychedelic in ...

Assembly Biosciences has dosed the first subject in the Phase Ia/b study’s Phase Ib portion, evaluating ABI-1179.